Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A2 | P23975 | 1/20 | 0.52 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.50 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.50 |
| ▸ | CTSC | P53634 | 1/20 | 0.49 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.48 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.48 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.48 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.48 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.48 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.48 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.48 |
| ▸ | ACACB | O00763 | 1/20 | 0.47 |
| ▸ | LMNA | P02545 | 1/20 | 0.47 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.47 |
| ▸ | NLRP3 | Q96P20 | 1/20 | 0.47 |
| ▸ | NOS2 | P35228 | 2/20 | 0.46 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.46 |
| ▸ | GRIN2D | O15399 | 1/20 | 0.45 |
| ▸ | GRIN3B | O60391 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2734777 | 1.00 | SLC6A2 (0.52) | SLC6A2SLC6A3ALDH1A1SLC6A4CTSC | |
| SCHEMBL241905 | 1.00 | SLC6A2 (0.52) | SLC6A2SLC6A3ALDH1A1SLC6A4CTSC | |
| Hydrochloric Acid SCHEMBL1168261 | 0.98 | ALDH1A1 (0.52) | SLC6A2SLC6A3ALDH1A1SLC6A4CTSC | |
| Hydrochloric Acid SCHEMBL1473550 | 0.98 | ALDH1A1 (0.52) | SLC6A2SLC6A3ALDH1A1SLC6A4CTSC | |
| Hydrochloric Acid SCHEMBL241904 | 0.98 | ALDH1A1 (0.52) | SLC6A2SLC6A3ALDH1A1SLC6A4CTSC | |
| SCHEMBL539261 | 0.95 | ROCK2 (0.52) | SLC6A2SLC6A3ALDH1A1SLC6A4CTSC | |
| SCHEMBL539262 | 0.95 | ROCK2 (0.52) | SLC6A2SLC6A3ALDH1A1SLC6A4CTSC | |
| Hydrochloric Acid SCHEMBL539617 | 0.94 | ROCK2 (0.51) | SLC6A2SLC6A3ALDH1A1SLC6A4CTSC | |
| Hydrochloric Acid SCHEMBL539618 | 0.94 | ROCK2 (0.51) | SLC6A2SLC6A3ALDH1A1SLC6A4CTSC | |
| Hydrochloric Acid SCHEMBL9584126 | 0.91 | FPR2 (0.54) | ALDH1A1SLC6A4PTGS2CYP1A2CYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 77 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-118307428-B | Chiral alpha unnatural amino acid and preparation method thereof by rare noble metal complex | 北京元延医药科技股份有限公司 | 2025-01-10 | — | — | CN | disclosed |
| US-11427552-B2 | Heterocyclic compounds useful in the treatment of disease | EPIGEN BIOSCIENCES, INC. (US) | 2022-08-30 | — | — | US | disclosed |
| CN-105142635-B | Heterocyclic compounds useful for the treatment of diseases | 艾匹根生物技术有限公司 | 2021-07-27 | — | — | CN | disclosed |
| EP-2988743-B1 | HETEROCYCLIC COMPOUNDS USEFUL IN THE TREATMENT OF DISEASE | EPIGEN BIOSCIENCES INC (US) | 2020-12-09 | — | — | EP | disclosed |
| US-20200181099-A1 | Heterocyclic Compounds Useful In The Treatment Of Disease | EPIGEN BIOSCIENCES, INC. (US) | 2020-06-11 | — | — | US | disclosed |
| US-10669242-B2 | Clostridium difficile toxin inhibitors | Venenum Biodesign, LLC (US) | 2020-06-02 | — | — | US | disclosed |
| US-10570103-B2 | Heterocyclic compounds useful in the treatment of disease | EPIGEN BIOSCIENCES, INC. (US) | 2020-02-25 | — | — | US | disclosed |
| US-20190194147-A1 | Novel Clostridium Difficile Toxin Inhibitors | Venenum Biodesign, LLC (US) | 2019-06-27 | — | — | US | disclosed |
| US-20190135767-A1 | Heterocyclic Compounds Useful In The Treatment Of Disease | EPIGEN BIOSCIENCES, INC. (US) | 2019-05-09 | — | — | US | disclosed |
| US-20180297962-A1 | Heterocyclic Compounds Useful In The Treatment of Disease | EPIGEN BIOSCIENCES, INC. (US) | 2018-10-18 | — | — | US | disclosed |
| EP-1140924-A1 | PIPERAZINE DERIVATIVES | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2001-10-10 | — | — | EP | disclosed |
| EP-1085869-A4 | SPIROPIPERIDINE DERIVATIVES AS MELANOCORTIN RECEPTOR AGONISTS | MERCK & CO INC (US) | 2001-10-04 | — | — | EP | disclosed |
| US-6294534-B1 | TREATMENT OF DISORDERS RESPONSIVE TO THE ACTIVATION OF MELANOCORTIN RECEPTORS, SUCH AS OBESITY, DIABETES OR MALE OR FEMALE SEXUAL DYSFUNCTION. | MERCK & CO., INC. | 2001-09-25 | — | — | US | disclosed |
| EP-1085869-A1 | SPIROPIPERIDINE DERIVATIVES AS MELANOCORTIN RECEPTOR AGONISTS | Merck & Co., Inc. (US) | 2001-03-28 | — | — | EP | disclosed |
| WO-2000035915-A1 | PIPERAZINE DERIVATIVES | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2000-06-22 | — | — | WO | disclosed |
| WO-1999064002-A1 | SPIROPIPERIDINE DERIVATIVES AS MELANOCORTIN RECEPTOR AGONISTS | MERCK & CO., INC. (US) | 1999-12-16 | — | — | WO | disclosed |
| CN-1233238-A | Acylaminoalkenylene-amide derivatives as NK1 and NK2 antagonists | NOVARTIS AG (CH) | 1999-10-27 | — | — | CN | disclosed |
| EP-0923550-A1 | ACYLAMINOALKENYLENE-AMIDE DERIVATIVES AS NK1 AND NK2 ANTAGONISTS | Novartis AG (CH) | 1999-06-23 | — | — | EP | disclosed |
| WO-1998007694-A1 | ACYLAMINOALKENYLENE-AMIDE DERIVATIVES AS NK1 AND NK2 ANTAGONISTS | NOVARTIS AG (CH) | 1998-02-26 | — | — | WO | disclosed |
| WO-1994025581-A1 | MODIFIED RECOMBINANT TISSUE PLASMINOGEN ACTIVATOR | SOUTHERN SYDNEY AREA HEALTH SERVICE (AU) | 1994-11-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190135767-A1 | Heterocyclic Compounds Useful In The Treatment Of Disease | LPAR1, LPAR2, LPAR4 | SLC6A2 4315/4885SLC6A3 4422/4885ALDH1A1 2204/4885 |
| US-20180297962-A1 | Heterocyclic Compounds Useful In The Treatment of Disease | LPAR1, LPAR4, LPAR2 | SLC6A2 3908/4885SLC6A3 4067/4885ALDH1A1 1649/4885 |
| US-20190194147-A1 | Novel Clostridium Difficile Toxin Inhibitors | GABRA5, GABRA1, GABRA4 | SLC6A2 837/4885SLC6A3 733/4885ALDH1A1 2381/4885 |
| US-11427552-B2 | Heterocyclic compounds useful in the treatment of disease | LPAR1, LPAR4, LPAR3 | SLC6A2 4690/4885SLC6A3 4237/4885ALDH1A1 1693/4885 |
| US-10669242-B2 | Clostridium difficile toxin inhibitors | GABRA5, GABRA1, GABBR2 | SLC6A2 726/4885SLC6A3 707/4885ALDH1A1 1908/4885 |
| US-20200181099-A1 | Heterocyclic Compounds Useful In The Treatment Of Disease | LPAR1, LPAR4, LPAR3 | SLC6A2 4690/4885SLC6A3 4237/4885ALDH1A1 1693/4885 |
| US-10570103-B2 | Heterocyclic compounds useful in the treatment of disease | LPAR1, LPAR2, LPAR4 | SLC6A2 4315/4885SLC6A3 4422/4885ALDH1A1 2204/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.